Replies to post #3042 on Enanta Pharmaceuticals Inc (ENTA)

[dewophile]

it looks like less than a day shorter symptom duration even on the restricted 6 symptom endpoint
VL curves do separate, but not by a lot and could be driven by the higher risk patients in the trial versus enanta
certainly based on symptom endpoint edp-235 looks more effective, especially given there were no high risk patients at all included, although I haven't compared the definitions for an apples to apples comparison
I have no idea if this resurrects any partnering prospects for 235

[vinmantoo]

Thanks, that new link worked. So Ensitrelvir shows anti-viral effects when assayed via nasal swabs but doesn't do much for symptom relief. I agree that seems to indicate that EDP-235 is superior. Now we just have to find someone willing got risk a few hundred million to confirm that. We should look under our sofa cushions and see if we can help raised the money. 🤣